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ABSTRACT 
Amani Alhejely S. M.S., Program in Microbiology and 
Immunology, Wright State University, 2011. Amino acid 
substitutions created in RT and their influence on HIV-1 
mutation frequencies. 
 
 
As research has shown, a high mutation rate occurs 
during the reverse transcription RT process because HIV 
reverse transcriptase fails to correct erroneously 
incorporated nucleotides during the reverse transcription 
process. Based on various research articles, a series of 
amino acid substitutions created in RT were collected to 
find out their influence on virus mutation frequencies. Two 
tables were used; one for amino acid substitutions created 
in RT that increased the HIV-1 mutation rate and another 
for amino acid substitutions created in RT that decreased 
the HIV-1 mutation rate. The tables show which amino acid 
substitutions created in RT decreased or increased the 
mutation rate of HIV-1. With more amino acid substitutions 
showing a decrease in the mutation rate of HIV-1, the 
tables provide researchers with helpful information for 
future research. Additionally, the information resulted in 
three new findings. First, When viewing single amino acids 
identified with drug resistance, most showed a decrease in 
the frequency of the mutation rate the of HIV-1; however, 
if the specified amino acid is not identified with drug 
 iv 
resistance most showed an increase in the HIV-1 mutation 
rate. Second, when HIV-1 has an increased mutation rate 
multiple amino acids showed drug resistance. Finally, a 
structural rationale for the location of residues 
implicated in the resistance of nucleoside-analog 
inhibitors (Huang et al., 1998) showed that mutations that 
decrease and/or increase the mutation rate do not cluster 
together. Those specified mutations are all around the 
active site in the crystal structure. Also, these amino 
acids might be in the primer grip region or interact with 
the incoming dNTP, and form the dNTP binding site or 
residues in the fingers subdomain. 
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INTRODUCTION: 
Since the beginning of the AIDS epidemic researchers 
have made great efforts to understand the nature of the 
human immunodeficiency virus (HIV). There are two known 
species of HIV,HIV 1 and HIV 2, which belong to the 
Lentivirus genus in the family Retroviridae. HIV virions 
like other retroviruses contain a viral capsid, which 
consists of the major capsid protein, p24; the nucleocapsid 
protein, p7/p9; the diploid single-stranded RNA genome; and 
the three viral enzymes, protease, reverse transcriptase, 
and integrase. The viral capsid is surrounded by a matrix 
protein and it is located underneath the virion envelope. 
The matrix protein is involved in the early stages of the 
viral replication cycle and plays an important role in the 
formation and transport of the preintegration DNA complex 
into the nucleus of the host cell. The envelope protein 
complex facilitates viral entry by binding to CD4, the main 
cellular receptor for all primate lentiviruses, via the 
outer envelope protein, which is gp120. The transmembrane 
protein, which is gp41, is involved in the fusion of the 
viral envelope with the cellular membrane (3).  
With HIV-infected persons who are not on 
antiretroviral therapy, HIV replicates at an 
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extraordinarily high rate, typically with billions of 
virions produced daily (50). A key result in the HIV life 
cycle takes place when HIV RNA is reverse transcribed into 
HIV DNA (23). The HIV DNA formed in the reverse 
transcription process is comprised of nucleotides organized 
into codons (23). The HIV DNA is then transcribed into 
messenger RNA (mRNA), with each mRNA nucleotide triplet 
coding for an amino acid. The relationship between amino 
acids results in the synthesis of a polypeptide, and large 
polypeptides are subsequently modified to form proteins. A 
high mutation rate occurs during the reverse transcription 
process because HIV reverse transcriptase RT fails to 
correct erroneously incorporated nucleotides during the 
reverse transcription process (50, 30). The changed 
nucleotide sequences can result in amino acid substitutions 
during translation, with the potential formation of a 
mutated protein (30). In the setting of selective pressure 
from an antiretroviral medication, the overall effect is 
the generation of viruses that may have diminished 
preferences to the medication and these mutated HIV strains 
are referred to as resistant strains of HIV (30). If a 
mutation produces an HIV strain resistant to one or more 
antiretroviral agents currently used by an individual, the 
resistant strain typically has a selective advantage over 
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the wild type virus, and it may eventually become one of 
the dominant circulating strains of HIV (30).  
 The aim of antiretroviral therapy is to completely 
suppress viral replication and delay drug resistance. An 
increasing viral load is often the sign that HIV drug 
resistance has developed. Resistance in HIV therapy is 
defined as the virus’ breakdown to respond following 
treatment and its subsequent active replication, or 
reproduction, of itself. It is possible that a person may 
have a virus that is resistant to a drug that the patient 
has never taken because the HIV in the patient 
spontaneously mutated and developed a resistance prior to 
treatment. Since each class of drug combats HIV in a 
different way, cross-resistance is not conveyed from one 
class to another; the three major classes of anti-HIV drugs 
are nucleoside reverse transcriptase inhibitors (NRTI), 
nonnucleoside reverse transcriptase inhibitors (NNRTI), and 
protease inhibitors (PI). Viral mutations may occur at a 
number of different places in the viral gename, and 
typically more than one mutation is needed for a virus to 
become drug resistant (1). 
 There are two types of antiretroviral resistance assays 
(drug-resistance assays) that are currently available to 
assist the clinician in assessing HIV resistance: genotypic 
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assays and phenotypic assays (22, 34, 30, and 24). Drug-
resistance assays are unique laboratory tests used by 
HIV/AIDS specialists to determine whether the virus 
infecting a patient is likely to respond to specific 
antiretroviral medications (24). Recently, some 
investigators have employed newer techniques, such as 
allele-specific PCR, single-genome, and ultra-deep 
sequencing, to assess the role of minority HIV variants 
that harbor drug resistance, but are not detectable by 
current standard genotypic or phenotypic assays (34,30). 
Both genotypic assays and phenotypic assays complement each 
other in treating and monitoring HIV/AIDS patients (30). 
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Table 1: Amino acid mutations, which result in a decrease in 
the mutation rate of nucleoside resistant of HIV-1 reverse 
transcriptase. 
Mutant 
sequence 
 Region Drug 
resistance 
Fold 
change1 
Type of 
assay 
Reference 
ddTTP Gap 
filling, 
F61A Fingers 
d4TTP 
12 
Gel based 
mispair 
extension 
assay 
[14] 
 
ddc 3.3 Replicatin
g Virus, 
[37] 
ddI 8 Forward 
lacZ 
[46] 
3TC 0.3 Gap 
filling 
  
K65R Fingers 
Multi-NRTI2       
In vitro, 
forward 
(gapped 
DNA), 
lacZ(274 
nt) 
[29] 
Replicatin
g Virus, 
[37] 
Forward 
lacZ 
  
L74V Fingers Abacavir & 
Didanosine 
(ddi) 
3.5 
Gap 
filling 
  
2.5 Replicatin
g Virus, 
[37] 
 
9.0-
14.0 
Forward 
lacZ 
[32] 
0.4 In 
vitro,Forw
ard lacZa 
  
D76V Fingers None 
Reported 
8.8 M13mp2 
lacZa 
forward 
mutation 
assay 
  
3.3 Replicatin
g Virus, 
[37]  
9 Forward 
lacZ 
[32] 
8.9 In 
vitro,Forw
ard lacZa 
  
R78A Fingers AZT/ 3TC 
0.3    
 6 
ddg In vitro , 
Forward 
(gapped 
DNA), lacZ 
a(274 nt) 
[29] 
 
3TC Replicatin
g Virus, 
[13] 
Forward 
lacZ 
[12] 
E89G Palm 
LOOK 
reference 
12 in #10 
2 
  [37] 
1.5-
2.0 
[5] 
1.2= 
wt 
[7] 
Y115F dNTP 
Binding 
abacavir 
  
In vitro , 
Forward 
(gapped 
DNA), lacZ 
a(174 nt) 
[8] 
[5] Y115V  dNTP 
Binding 
None 
Reported 
3.0-
4.0 
In vitro , 
Forward 
(gapped 
DNA), lacZ 
a (174 nt) 
[7] 
Multi-NRTI 
(Part of 
151 
complex)3 
5 Replicatin
g Virus, 
[37] 
 
AZT 13 Forward 
lacZ 
[51] 
  0.2 Misincorpo
ration RT 
assay 
  
Q151N dNTP 
Binding 
 5.7 M13 lacZa 
forward 
mutation 
assay 
[52] 
Replicatin
g Virus, 
Forward 
lacZ 
K154A dNTP 
Binding 
None 
Reported 
2.1 
Misincorpo
ration RT 
assay 
[51] 
 
ddI/ddc/AZ
T 
In vitro , 
Forward 
(gapped 
DNA), lacZ 
a (274 nt) 
[39] 
  
Multi-NRTI4 [49] 
[13] 
M184V Palm 
 
2.4 
Mismatched 
primer 
extension 
assay  
ddI/ddc M184I Palm 
Multi-NRTI5 
4 Forward 
assay 
[43] 
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2 W229A Primer 
Grip 
None 
Reported 0.5 
Replicatin
g Virus, 
Forward 
lacZ 
[37] 
Y318F Thumb Efavirenz 
& 
Nevirapine 
(NNRTIs) 
1.4 Replicatin
g virus, 
Reversion 
luc 
[8] 
 
T69I+AZT+I
nsertion 
Fingers Multi-NRTI6 1.4 Replicatin
g virus, 
Reversion 
luc 
[8] 
 
Multi-NRTI6 4.0-
16.0 
M13 gapped 
duplex 
DNA, lacZ 
[10] 
AZT 9 Virion- 
associated 
RT 
inhibition 
asay 
[33] 
 
T69s+Inser
tion+-AZT 
Fingers 
      [53] 
Replicatin
g Virus, 
D76V/R78A dNTP 
Binding 
None 
Reported 
9 
Forward 
lacZ 
[37] 
Replicatin
g Virus, 
R78A/Q151N Fingers 
& dNTP 
Binding 
Multi-
NRTI(part 
of 151 
complex)3 
14.3 
Forward 
lacZ 
[37] 
2.2 K103N/Y318
F 
Palm&Thu
mb 
Efavirenz 
& 
Nevirapine 
(NNRTIs) 
2.69 
Replicatin
g virus, 
Reversion 
luc 
[8] 
 
Mismatch 
extension 
assay 
Running 
start 
fidelity 
assay 
R72A finger None 
Reported 
3.3 
Standing 
start 
fidelity 
assay lacz 
? read it 
again 
[35] 
 
W229A   Misamatch 
extension 
assay 
[54] 
AC:AG 
  None 
Reported 
2 Running 
start 
fidelity 
assay 
[37] 
 8 
   0.5 Standing 
start 
fidelity 
assay 
  
F227A   Miamatch 
extension 
assay 
[54] 
5.5 Running 
start 
fidelity 
assay 
[37] GA:CA 
  None 
Reported 
  Standing 
start 
fidelity 
assay 
  
V148I ? None 
Reported 
3.8 M13 lacZa 
forward 
mutation 
assay 
[52] 
1statistically significant with associated p-value < 0.05  
Relative to wild type. 
2Abacavir, Didanosine, Emtricitabine, Lamivudine, Tenofovir 
3see references{26, 46} 
4Abacavir, Emtricitabine, Lamivudine 
5Emtricitabine, Lamivudine 
6Zidovudine, Lamivudine, Stavudine, Didanosine, Zalcitabine 
7Most frequent in patient treated with efavirenz (NNRTI)-
containing therapies  
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Table 2: Increase in the mutation rate of nucleoside 
resistant of HIV-1 reverse transcriptase. 
Mutant 
Sequence 
RT 
region 
Drug 
Resistance(s) 
Fold 
change 1 
Type of assay Reference 
 
Y115A 
 
dNTP 
Bindin
g 
palm 
AZT 4.0 
2.3 
In vitro , 
Forward 
(gapped 
DNA), lacZ 
α(274 nt) 
Replicating 
Virus, 
Forward 
lacz 
[29] 
[37] 
Y183F palm efavirenz 1.6 In vitro , 
Forward 
(gapped 
DNA), lacZα 
(274 nt) 
Mismatch 
extension 
assay 
Running 
start 
fidelity 
assay 
(1.2) 
[29] 
[54] 
 
 
 
[8] 
F227A 
A:A 
Primer 
Grip 
None Reported 
 
5.5 In vitro , 
Forward 
(gapped 
DNA), lacZ 
α (274 nt) 
Mismatch 
extension 
assay 
Running 
start 
fidelity 
assay 
[29] 
[54] 
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W229A 
A:A 
Primer 
Grip 
None Reported 
 
27 Mismatch 
extension 
assay 
Running 
start 
fidelity 
assay 
3 assay 
 
[54] 
 
[37] 
Q258A Thumb 
 
None Reported 
 
2.3 In vitro, 
framshift 
[4] 
G262A Thumb 
 
None Reported 
 
4.4 In vitro, 
Forward 
lacz a 
 
[2] 
[3] 
[37] 
W266A Thumb 
 
None Reported 
 
3.2 In vitro , 
Forward 
(gapped 
DNA), lacZ 
α (274 nt) 
 
[2] 
[3], 
[37] 
Q269A 
 
Thumb 
 
None Reported 
 
2.6 
3.5 
In vitro , 
Forward 
(gapped 
DNA), lacZ 
α (274 nt) 
In vitro, 
framshift 
(4nt) 
[2] 
[4] 
Y501W 
 
 
RNaseH 
Primer 
Grip 
None Reported 
 
2.7* Replicating 
Virus, 
Forward 
lacz 
[37] 
M41L/T21
5Y 
 
Finger
s & 
palm 
AZT (NRTI) 
3TC 
 
2.0* 
3.3 
Replicating 
Virus, 
Forward 
lacz 
[36] 
M41L/D67
N/K70R/T
215Y 
 
Finger
s & 
palm 
AZT (NRTI) 
3TC 
3.0* 
4.3 
Replicating 
Virus, 
Forward 
lacz 
[36] 
L74V/Y11
5F/M184V 
 
Finger
s & 
palm 
Abacavir 
and 
Zalcitadine 
(NRTIs) 
1.91 
3.39 
Replicating 
Virus, 
Reversion 
luc 
[8] 
[29] 
 11 
Y115WW/M
230I 
 
Primer 
grip & 
dNTP 
Bindin
g 
None Reported 
 
3-.35 Misinsertio
n/mispair 
extension 
assay 
In vitro, 
Forward 
lacz  α 
[17] 
R72A Finger None Reported 
 
3.3 Misamatch 
extension 
assay 
Running 
start 
fidelity 
assay 
Standing 
start 
fidelity 
assay 
[35] 
Q151N/ 
R78A 
 AZT 
3TC 
 
Hu 
Thy 
TG 
13/9  Replication 
a lacz α 
 
[37] 
W229A 
A:A 
 None Reported 
 
27 Misamatch 
extension 
assay 
Running 
start 
fidelity 
assay 
Standing 
start 
fidelity 
assay 
[54] 
F227A 
A:A 
 NNRTI 5.5 Misamatch 
extension 
assay 
Running 
start 
fidelity 
assay 
Standing 
start 
fidelity 
assay 
[54] 
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As shown in tables 1 and 2 when viewing single amino acids 
identified with drug resistance, most showed a decrease in 
the frequency of the mutation rate the of HIV-1 genome ; 
however, if the specified amino acid is not identified with 
drug resistance most showed an increase in the HIV-1 
mutation rate: 
In untreated patients, HIV undergoes mutations at every 
position in the genome numerous times a day, allowing the 
emergence of viruses that can evade the immune response 
(10). Studies of in vivo viral dynamics have estimated the 
viral turnover to be 107 to 109 in a single patient, with 
the in vivo half-life of a virion estimated at 2 days (41, 
42). This large, short-lived population of virus is 
sustained by a rapid rate of viral replication. 
Calculations of probable viral growth rates and mutation 
frequencies suggest that the replication rate is sufficient 
to create a population of viruses of sufficient diversity 
to respond to any immunological or pharmacological 
challenge.  
Drug-resistant viruses have a greater ability to 
replicate under conditions of drug pressure when compared 
to the wild type as determined via viral fitness 
measurements (10). Conversely, the overall rate of 
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replication for most drug resistant viruses is lower than 
that of the wild type virus in the absence of treatment 
(34). This lowered replication rate, referred to as 
decreased viral fitness, can affect the rate of appearance 
of new variants (33). Therefore, nucleoside-analog 
resistance mutations in RT can contribute to the rate of 
emergence of new viral variants. Thus, a good understanding 
of the influence of drug resistance mutations on viral 
mutation rate and viral variation remains an important goal 
of HIV research.  
HIV-1 forward mutation frequencies have been analyzed 
in a single round of replication in culture using HIV-1 
vectors containing reporter genes lacZ and tk, or in vitro 
using gapped DNA repair and other types of assays (see 
Tables 1&2). A series of amino acid substitutions were 
created in RT to find out their influence on virus mutation 
frequencies. The focus of the current study is on amino 
acid residues that were targets for site directed 
mutagenesis, generally chosen based on their involvement in 
drug resistance. These data indicate that single amino 
acids associated with drug resistance mostly showed a 
decrease in the frequency of the mutation rate of the HIV-1 
genome; however, if the specified amino acid is not 
associated with drug resistance most showed an increase in 
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the HIV-1 mutation rate (Tables1 and 2). 
  Some studies tested these mutations to determine what 
influence they would have on virus mutation frequencies by 
using an assay for measuring the HIV-1 mutation frequency 
in one round of replication. In some cases, researchers 
chose residues located in the finger and palm subdomains 
such as F61, K65R, L74V, D76V, R78A, R72A, which confere 
resistance to drugs such as ddTTP, d4TTP, ddc, ddI, 3TC, 
and combinations likeNRTI andAZT. 
  In Tables 1 all single-amino-acid substitutions in RT 
that significantly decreased HIV-1 mutation frequencies 
confered drug resistance, except D76V and R72A, for which 
drug resistance has not yet been reported. Also, mutations 
E89G, M184V, and M184I, located in the palm subdomain 
confer drug resistence to ddI, ddc, AZT, and combinations 
of NRTI5, ddg and 3tc. 
  In other cases, researchers chose amino acid residues 
that interact with the incoming dNTP and form the dNTP 
binding site identified in structural studies. For example, 
a mutation in the dNTP binding site of HIV-1 RT, Q151N, has 
been reported to increase fidelity by a factor of 13, using 
lacZ  or a factor of 5.7  using M13 lacZ a forward mutation 
assay (51). The Q151 residue in RT is implicated in drug 
resistance to multiple drugs. Also, there is Y115F has been 
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reported to increase fidelity by factors of 1.5 to 2.0 by 
using forward gapped DNA repair (7).  
In other studies, the focus was on amino acids in the 
primer grip. The αH helix motif of the HIV-1 RT thumb 
subdomain binds to the minor groove of the template-primer 
complex and is connected with alterations in RT 
processivity and fidelity. The 3‘ end of the primer is 
positioned close to the RT active site by conserved 
residues 224 to 335 on the B11b loop and the β12 and β13 
hairpins (37). The region bound by residues 227 to 235 is 
considered the primer grip (37). The W229A mutation in the 
αH helix has been reported to modify misincorporation and 
mispair extension frequencies, presumeably through an 
increase in the rate of RT dissociation from the template 
DNA or through an increase in strand slippage resulting in 
lower enzyme fidelity (54). These mutations in RT were 
tested to determine what influence they would have on virus 
mutation frequencies by using an assay for measuring the 
HIV-1 mutant frequency in one round of replication. The 
W229A RT variant influenced virus mutant frequencies. The 
W266 and G262A residues are located in the thumb domain and 
have been found to increase HIV-1 RT cell-free fidelity in 
the lacZ reporter assay (37). The W266A and G262A variants 
have decreased fidelity for template-primer slippage 
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errors, such as frameshift and deletion mutations; drug 
resistance has not yet been reported for these. Another 
point of interest is amino acid residues in the RNase H 
domain. The RNase H domain is responsible for the RNase H 
activity essential for the degradation of the viral RNA 
present in the RNA-DNA replication intermediate, allowing 
the DNA to act as a template for the DNA-dependent DNA 
polymerase activity of RT to complete synthesis of the 
double-stranded viral DNA. The RNase H activity of RT is 
necessary for the strand transfered that occur during 
reverse transcription. Amino acid residues in the RNase H 
domain that are involved in the RNase H primer grip contain 
residues 473 to 476, 501, and 505. Some researchers tested 
whether residues in the RNase H primer grip could influence 
virus mutant frequencies. In particular mutation at Y501  
was analyzed. Analysis of these RT variants on virus mutant 
frequencies indicated that Y501W significantly influenced 
virus mutation frequencies compared to wild-type RT; drug 
resistance for this location has not yet been reported 
(37). 
In summary, several RT variants with single amino-acid 
changes have been characterized in both the polymerase and 
RNase H domains that influence virus mutation frequencies 
and have been implicated in drug resistance to multiple 
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drugs. Many mutations that increase mutation rate have not 
yet been implicated in drug resistance. 
When HIV-1 has an increased mutation rate multiple amino 
acids showed drug resistance: 
Most drug-resistant RT enzymes that increase the viral 
mutation rate have multiple amino acid substitutions. Some 
researchers have been identified several amino acid 
residues in RT that, when mutated, can significantly alter 
virus mutant frequencies. Researchers tested whether the 
mutated residues could act together to alter virus mutant 
frequencies by analyzing a series of RT variants with 
combined mutations. The variants tested integrated the 
D76V/R78A, R78A/Q151N mutations, which corresponded to 
mutations in the finger subdomain. The HIV-1 RT variants 
included either the D76V/R78A(-) or the R78A/Q151N(-,+) 
double mutation. These substitutions led to mutation 
frequencies that were significantly lower than the 
frequencies of wt HIV-1 (Tables 1 and 2). It was shown that 
the mutation frequency of R78A/Q151N was appreciably lower 
than the variants with each mutation alone, while the 
mutation frequency of D76V/R78A was significantly lower 
than that of the R76V RT variant but not that of the R78A 
RT variant alone (37). As shown in Table 2 the drug 
resistance mutation that identified an increase in HIV 
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mutation frequency represents a combination of mutations in 
HIV-1 RT. For example, M42L/T215Y, M41L/D67N/K70R/T215Y, 
Y115W/M230I and Q151N/R78A have been implicated in drug 
resistance to AZT, 3TC, abacavir and NRTI. The data support 
the conclusion that most of the drug resistance mutations 
that increase virus mutation frequencie functions as 
residues in RT that act together. 
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Figure 1: Images from the Swiss-PdbViewer software-assisted 
visualization of the amino acid residues in RT that lead to 
decrease or increase mutation rate.  
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Figure 1-a: The image shows the residues for which mutation 
leads to a decrease in mutation rate are colored in purple, 
the residues mutation leads to increase in mutation rate 
are colored in orange, the residues who mutation leads to 
increase and decrease in mutation rate are colored in 
green, Mg cations (red) and the protein backbone color in 
white:(left side) 
  
a 
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1-b (right side) 
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Figure 2: Close-up of each of the grouped amino acid 
residues: 
a 
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b 
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Mutations that decrease and/or increase the mutation rate 
do not cluster together. They are all around the active 
site: 
 The structure of a ternary complex with dNTP bound at 
the active site gave a more detailed explanation of the 
dNTP-binding pocket, and provided a structural rationale 
for the location of residues implicated in resistance to 
nucleoside-analog inhibitors (25). The ternary structure 
suggests that upon binding of the dNTP substrate, HIV-1 RT 
forms a closed structure, whereby residues in the fingers 
subdomain become a component of the binding pocket (25). A 
number of residues in this region are mutated in 
nucleoside-analog resistant variants, and have also been 
shown to affect the fidelity of HIV-1 RT (25). As shown in 
Table 1 and 2 and Fig 1 and 2, mutations that decrease 
and/or increase the mutation rate do not cluster together. 
They are all around the active site. These amino acids are 
residues in the fingers subdomain or primer grip region of 
HIV-RT or represent residues that interact with the 
incoming dNTP and form the dNTP binding site. As previously 
mentioned, the primer grip region (residues 227–235) 
correctly positions the 3‘ ends of primers. Point mutations 
were formed by alanine substitution at positions 224–235 
and error frequencies were measured by extension of a dG:dA 
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primer-template mismatch. Wisniewski et al. (1999) found 
that mutants F227A and W229A extended the dG:dA mismatch 
40% and 66% less efficiently, respectively, as compared 
with the wild type. These researchers also examined the 
misinsertion rates of dG, dC, or dA across from a DNA 
template dA using RT mutants F227A and W229A. They used 
running start misinsertion assay on a template that allows 
misalignment Synthesis. They also performed a running start 
experiment using substrate A. In this experiment the 
template has two T residues and one G after the 3 // end of 
the annealed primer and it is similar to substrate E. After 
the G, the substrate A template has two additional T 
residues that possibly promote a misalignment. By this 
mechanism, once the first two T residues in the template 
are extended by RT, the last A of the primer can bind to 
the next set of T residues in the template, and it causes 
the G to loop out. By that the third or fourth A could be 
added. Then the enzyme can continue synthesis with the G 
looped out to create a deletion. On the other hand, the 
third A added to the primer could mispair with the G and 
the fourth could correctly pair with a T, allowing further 
extension. They observed F227A and wild type RTs 
synthesizing a misinsertion of an A across from a G on this 
template. Mutant F227A did not extend past the misinsertion 
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as efficiently as the wild type RT, because the mutant 
required a several fold higher concentration of dATP in 
order to sustain comparable synthesis past the mismatch. 
Also, mutant F227A was not able to make a detectable 
misincorporation product with the same mismatch on 
substrate E, which did not contain the two T residues after 
the G on the template. It suggests that the two T residues 
in substrate A promote extension past the G in the template 
and that the F227A mutant uses the misalignment mechanism 
for this process. It is possible that F227A misinserted an 
A across from a G. Misinsertion cauld have been favored by 
the particular sequence context of substrate A. They found 
W229A was not able to catalyze an A misinsertion across 
from G, similar to its behavior on substrate E, and this 
mutant was not able to catalyze extension of a misalignment 
like F227A or wild type RT. Especially, the F227A mutant 
catalyzed the dA:dG misincorporation and mismatch extension 
with a lower efficiency than the wild type RT. Also, 
extension past the 32-nucleotidelong product by F227A to 
create longer products having a mismatch required a 40-fold 
higher concentration of dATP in order to generate an equal 
amount of extension products as compared with wild type RT. 
In contrast, F227A extended the DNA primer to create a 38-
nucleotide product at 0.5 mM dATP. This product is hardly 
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visible with the wild type RT at all concentrations of dATP 
added. To make this extension product, the mutant had to 
misinsert three A nucleotides across from three A residues 
in the template. They found the F227A mutant was more 
efficient at creating and extending dA:dA mismatches than 
the wild type RT. They conclude that the F227A mutant 
displays higher fidelity for dA:dG mismatches and lower 
fidelity for dA:dA mismatches than wild type.  So their 
result shows that a single amino acid substitution can 
increase or decrease fidelity, depending on the base pair 
being formed in the reaction. 
They found that mutant W229A exhibited high fidelity 
and did not produce a dG:dA or dC:dA mismatch. Also, mutant 
F227A displayed high fidelity for dG:dA and dC:dA 
mismatches but low fidelity for dA:dA misinsertions. This 
indicated that F227A discriminates in opposition to 
particular base substitutions. Also, a primer extension 
assay with three dNTPs showed that F227A generally displays 
higher fidelity than the wild type RT. Noticeably, primer 
grip mutations can improve or worsen either the overall or 
base-specific fidelity of HIV RT. They hypothesized that 
wild type RT has evolved to a fidelity that allows genetic 
variation without compromising yield of viable viruses. 
After HIV-RT has secured onto the DNA (or RNA) 
 28 
template, it faces the job of adding base specific 
nucleotides (dNTPs) to produce a new daughter strand (38). 
With the stabilizing features of the polymerase site, there 
are also RT-template or RT-metal interactions that 
stabilize the dNTP binding site and promote the 
polymerization reaction. A majority of these stabilizing 
interactions are found within the palm domain, contacting 
the minor groove of DNA. Tyr 183 (+) which hydrogen bonds 
to the minor groove, increased HIV-RT mutation rate. There 
stands a multitude of amino acids that coordinate the 
triphosphate moiety. For instance, the sidechain of Arg 72 
which was found to both increase and decrease the mutation 
rate, lies flat against the dNTP base, donates hydrogen 
bonds to the alpha-phosphate and esterified oygen bridging 
the alpha and beta phosphates. The NH group of Lys 65 that 
decreased HIV-RT mutation rate also donates hydrogen bonds 
to the gamma phosphate at both the esterified, and non-
esterified oxygens. The main chains of Asp 113 and Ala 114 
(not shown in the table), give hydrogen bonds to the beta 
and gamma phophates, respectively, while the main chain-NH 
of Tyr 115 which both increases and decreases the mutation 
rate donates a hydrogen bond to the 3'OH of the incoming 
dNTP (38).  
 It can be concluded that the mutations that decrease 
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and/or increase the mutation rate do not cluster together. 
They are all around the active site in the crystal 
structure. Also, these amino acids might be in the primer 
grip region or interact with the incoming dNTP and form the 
dNTP binding site or residues in the fingers subdomain. 
 
Discussion: 
 Nucleoside-analog inhibitors of HIV-1 RT were the 
first drugs used against the virus. It is known that 
monotherapy with these and other drugs leads to the rapid 
development of viral resistance. Also, it is being 
increasingly appreciated that a significant percentage of 
individuals receiving highly active antiretroviral therapy 
(HAART) also develop resistance. RT is responsible both for 
optimal rate of replication and an accurate copying of the 
viral genome, the consequence of drug resistance mutations 
in RT to the biochemistry of this enzyme and to the biology 
of the virus are critically important. In this review, we 
describe a number of studies investigation the polymerase 
fidelity of nucleoside-analog resistant HIV-1 reverse 
transcriptase as well as the mutation rate of HIV-1 
harboring these mutations (44). 
As shown in Tables (1 and 2), several RT variants with 
single amino-acid changes have been characterized in both 
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the polymerase and RNase H domains that decrease virus 
mutation frequencies have been implicated in drug 
resistance to multiple drugs. Many single amino-acid 
changes in the polymerase and RNase H domains that increase 
mutation rate have not yet been implicated in drug 
resistance. Also, as shown in Tables (1 and 2) drug 
resistant mutations that increase HIV mutation are found in 
combinations. 
The mutation rate of HIV-1 is influenced by a 
multiplicity of viral and host factors (44). The 
contribution of the virus to this variation includes three 
things. First, the high error rate of HIV-1 reverse 
transcriptase is estimated to be 3 x 10-5 per base per 
replication cycle (20). Second, the diploid nature of the 
genome facilitates recombination between the two RNA 
genomes (44). Finally, the high rate of viral replication 
(10). The host contributes to viral variation by the use of 
the cellular machinery for transcription, physiological 
fluctuations in dNTP pools, and asymmetric error repair. 
With the generation of errors, variation is further 
affected by a variety of selective forces. Examples of 
selective forces involve the relative fitness of a given 
mutant virus, the balance between the abundance of specific 
cell types, the cell tropism of a given variant of HIV, and 
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the action of the immune system. Some studies show that the 
host and virus act together to produce G-to-A 
hypermutations (44). Host cells produce a protein known as 
APOBEC3G, a DNA deaminase, which is packaged in the virion 
leading to the deamination of deoxycytosine residues in the 
first strand of viral DNA synthesized during reverse 
transcription to deoxyuracil. Therefore, APOBEC3G serves a 
host-encoded antiviral function by producing a large number 
of G-to-A mutations in the HIV-1 genome, thus rendering it 
nonfunctional. The virally encoded protein Vif allows HIV 
to overcome the activity of APOBEC3G, resulting in a non-
lethal level of G-to-A mutations, and contributing to the 
overall viral variation. Although all of these factors 
contribute to the overall mutation rate, a principal 
consideration is the viral RT, which is itself subject to 
alteration by mutations and selection during the course of 
disease and treatment. The majority of drug combination 
protocols used currently include nucleoside analogs that 
target RT. Resistance to this class of drugs develops 
through mutations that affect (44). 
A dose-dependent association between increased drug 
concentration and increased virus mutation frequency has 
been reported for zidovudine, lamivudine, and 
dideoxyinosine (36, 37). The maximum increase in virus 
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mutation frequency in the presence of dideoxyinosine was 
six fold higher than the virus mutation frequency observed 
during replication in the absence of drug. Chen et al. 
(2005) indicate that increased virus mutation frequencies 
occur when drug concentrations increase. 
Chen et al (2005) theorized that both RT variants and 
drugs together could increase virus mutation frequencies 
(36). Chen et al (2005) tested this ideaby using selected 
NRTIs and drug-resistant RT variants and analyzing them for 
their influence on virus mutation frequencies. They found 
mutant viruses containing either the Y115F or the 
L74V/Y115F/M184V RT mutations could grow in the presence of 
abacavir at its IC50 concentration. Both mutations were 
associated with a statistically significant increase in 
virus mutation frequency compared to those observed through 
virus replication with the wild-type RT in the presence of 
abacavir. Chen et al (2005) also observed that HIV-1 
replication with the L74V/Y115F/M184V RT variant in the 
presence of zalcitabine significantly influenced HIV-1 
mutation frequencies compared to that observed during virus 
replication with wild-type RT in the presence of 
zalcitabine (3.39-fold versus 1.36-fold). Also, in the 
presence of stavudine, the V75T RT variant affected virus 
mutation frequency as compared to wild-type RT (3.46-fold 
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versus 1.65-fold) (9).	  
It is important to understand the influence of 
mutations on viral properties such as replicative fitness, 
fidelity, and mutation rates. It is considered that the 
increased fidelity of K65R RT is due to an altered 
interaction with the dNTP substrate. 
Insight into residues that constitute the dNTP-binding 
pocket as well as mechanisms by which mutations at 
different sites may confer drug resistance or increased 
fidelity was provided by the shah crystal structure of a 
covalently trapped catalytic complex of HIV-1 RT with 
template-primer and dTTP (46).  In some studies the 
researchers found the presence of dNTP substrate in the 
binding pocket led to a conformational change involving an 
inward movement of the finger β3–"β4 hairpin loop, bringing 
it closer to the active site. In that conformation, the 
residues in the β3–"β4 hairpin loop, a lot of which are 
implicated in nucleoside analog resistance, directly 
contact the incoming dNTP, as well as indirectly influence 
its binding through interactions with the templating base. 
For example, the ammonium group of Lys65 contacts the γ-
phosphate of the dNTP, whereas its aliphatic portion 
interacts with Arg72. Also, Leu74 locks the templating base 
tightly in place and contacts the side chain of Arg72 and 
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Gln151, which in turn stack on the base of the dNTP. All of 
these residues except Arg72 are changed in variant viruses 
displaying resistance to nucleoside analogs. A Lys-to-Arg 
substitution at codon 65 associated with resistance to ddC 
and cross-resistance to 3TC and ddI was first reported by 
Gu et al. This mutation was shown to confer cross-
resistance to (9R)-2-phosphonylmethoxyethyladenine (16) and 
to bisisopropyloxymethylcarbonyl (48). A Leu-to-Val 
substitu- tion at codon 74 is the most frequently described 
mutation in patients taking ddI (53) and confers a 5–10-
fold decrease in sensitivity to ddI. Also, The L74V 
substitution has been shown to confer cross-resistance to 
ddC and 3TC, although both mutations can be found in a 
single patient, they usually exist as separate viral quasi-
species. When wild-type RT is compared with K65R RT, it is 
clear that K65R RT tended to generate very few products 
beyond the template site that served as a barrier. The 
wild-type residues at positions 65 and 74 create key 
contacts with the incoming dNTP and stabilize the 
templating base, respectively. In addition, the 
differential effect on mutation rate by substitutions at 
both residues that confer resistance to nucleoside analogs 
is intriguing. It appears that the alteration at Lys65 
leads to an ability to discriminate against several 2- 
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deoxy-NTP analogs as against non-Watson-Crick base-paired 
incoming dNTPs. On the other hand, the effects of the L74V 
substitution appear to be limited to discrimination against 
2- deoxy analogs(46). 
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